Biodistribution and internal dosimetry of the Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas

Nuclear Medicine Communications

Volumn 29, Issue 1, 2008, Pages 66-75

  Torres, Leonel A ^a   Coca, Marco A ^a   Batista, Juan F ^a   Casaco, Angel ^a   Lopez, Gerardo ^a   García, Ivan ^a   Perera, Alejandro ^a   Peña, Yamilé ^a   Hernández, Abel ^a   Sanchez, Yolaine ^a   Romero, Susana ^a   Leyva, Rene ^a   Prats, Anais ^a   Fernandez, Ramses ^a  

^a CENTRO INTERNACIONAL DE RESTAURACIÓN NEUROLÓGICA CIREN   (Cuba)

Author keywords

Biodistribution; Dosimetry; H R3; Nimotuzumab; Radioimmunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; NIMOTUZUMAB; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM; NIMOTUZUMAB RE 188; RHENIUM 188; UNCLASSIFIED DRUG;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; BODY BURDEN; BRAIN TUMOR; CLINICAL TRIAL; FEMALE; GLIOMA; HUMAN; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; RADIATION DOSE; RADIATION INJURY; RADIATION RESPONSE; TISSUE DISTRIBUTION; ANTIBODY LABELING; ANTIBODY RESPONSE; BLADDER; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; DRUG DOSE ESCALATION; DRUG EFFICACY; GLIOBLASTOMA; HEADACHE; KIDNEY; LIVER; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TREMOR; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BODY BURDEN; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GLIOMA; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORGAN SPECIFICITY; RADIATION DOSAGE; RADIATION INJURIES; RADIOISOTOPES; RADIOPHARMACEUTICALS; RHENIUM; TISSUE DISTRIBUTION;

EID: 39149091049     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282f1bbce     Document Type: Article

References (30)

1. Paganelli G, Bartolomei M, Grana C, Ferrari M, Rocca P, Chinol M. Radioimmunotherapy of brain tumour. Neurol Res 2006; 28:518-522.
2. Zalutsky MR. Current Status of therapy of solid tumours: brain tumour therapy. J Nucl Med 2005; 46:151S-156S.
3. Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo M. Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med 2000; 27:601-609.
4. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE II, et al. Salvage radioimmunotherapy with murine iodine-131-labelled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumours: phase II study results. J Clin Oncol 2006; 24:115-122.
5. 131I-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol 2006; 24:3644-3650.
6. Epenetos AA, Courtenay-Luck N, Pickering D, Hooker G, Durbin H, Lavender JP, et al. Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen. BMJ 1985; 290:1463-1466.
7. 125I-labelled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Rad Oncol Biol Phys 2004; 58:972-975.
8. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Perez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997; 3:71-81.
9. 99mTc in patients with tumour of epithelial origin. Nucl Med Commun 2005; 26:1049-1057.
10. Crombet T, Torres L, Neninger E, Catala M, Perera A, Torres O, et al. Pharmacological evaluation of the humanized anti-epidermal growth factor receptor monoclonal antibody, h-R3, in patients with advance epithelial cancer. J Immunother 2003; 26:139-148.
11. Crombet T, Ramos M, Osorio M, Cruz T, Roca C, del Castillo R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22:1646-1654.
12. 99mTc-labelled anti-human Epidermal Growth Factor Receptor Antibody (ior egf/r3) in patients with tumour of epithelial origin: II. Pharmacokinetics and clearances. J Nucl Med 1998; 39:1918-1927.
13. 188osmiun after the intracerebral administration in rats. Exp Toxicol Pathol 2005; 56:313-319.
14. 99mTc: Comparative planar and SPECT evaluation in a phantom study and implications for dosimetry. World J Nucl Med 2002; 1:12-20.
15. 188Re-labelled radiopharmaceuticals for radionuclide therapy. Nucl Med Commun 2006; 27:223-229.
16. 188Re. Nucleus 2003; 33:64-68.
17. 99mTc-labelled monoclonal antibodies. J Nucl Med 1987; 28:721.
18. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999; 40:37S-61S.
19. 90Y-biotin: dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med 1999; 26:110-120.
20. Ljungberg M, Larsson A, Johansson L. A New collimator simulation in SIMIND based on the delta-scattering technique. IEEE Trans Nucl Sci 2005; 52:1370-1375.
21. Bolch WE, Bouchet LG, Robertson JS, Wessels BW, Siegel JA, Howell RW, et al. The dosimetry of nonuniform activity distributions - radionuclide S values at the voxel level. MIRD Pamphlet No. 17. J Nucl Med 1999; 40:11-36.
22. 188Re labelled h-R3 locoregional RIT. In: Proceedings of IAEA International Conference on Quality Assurance and New Techniques in Radiation Medicine. IAEA-CN-146. Vienna: IAEA; 2006. pp. 92-94.
23. 188Re en una geometría voxel. Revista de Física Médica 2006; 7:101-106.
24. Stabin MG. MIRDOSE - the personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37:538-546.
25. G; Stabin M, Erdi Y, Akabani G, Kwok C, Bertrand BA, et al. Red marrow dosimetry for radiolabelled antibodies that bind to marrow, bone, or blood components. Med Phys 2000; 27:2150-2164.
26. Eller JL, Longo SL, Hicklin DJ, Canute GW. Activity of anti-epidermal growth factor receptor monoclonal antibody c225 against glioblastoma multiforme. Neurosurgery 2002; 51:1005-1014.
27. Iznaga-Escobar N. Direct radiolabeling of monoclonal antibodies with rhenium-188 for radioimmunotherapy of solid tumors - a review of radiolabeling characteristics, quality control and in vitro stability studies. Appl Radiat Isot 2001; 54:399-406.
28. Wersall P, Ohlsson I, Biberfeld P, Collins VP, Krusenstjerna S, Larsson S, et al. Intratumoural infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunother 1997; 44:157-164.
29. 131I-labelled anti-tenascin monoclonal antibody 81C6 therapy. Int J Rad Oncol Biol Phys 2000; 46:947-958.
30. Goetz C, Riva P, Poepperl G, Gildehaus FJ, Hischa A, Tatsch K, et al. Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J Neurooncol 2003; 62:321-328.